Science & Technologies

Epigeneron is committed to providing highly validated revolutionary drug targets to the healthcare industry discovered with our innovative platform, the locus-specific ChIP technology, resulting in accelerating the discovery and development of new drugs and the improvement of patient treatments.

Epigeneron also offers the ORNi-PCR technology which enables the specific amplification of DNA with mutations in heterogeneous DNA populations. It can be applied to the diagnostics area and the existing testing methodologies such as next-generation sequencing (NGS).

See below for more information.


Novel target discovery using
locus-specific ChIP

DNA is associated with proteins and RNAs to form chromatin which regulates gene functions such as epigenetic regulation and transcription. Comprehensive understanding of chromatin and the mechanisms of such genome functions requires the identification of molecules that bind to the genomic regions of interest in vivo.


ORNi-PCR to detect rare target

DNA sequence variants are known to be involved in the emergence of intractable diseases such as cancer. Various methods using PCR have been employed to detect the presence or absence of DNA mutations known to cause these diseases. However, conventional PCR-based methods have several limitations, such as sensitivity, cost, and ability to provide a definitive diagnosis.

Get In Touch